Lynx1 Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Lynx1 Capital Management LP
CRD #310301
SEC #801-127585
CIK #0001910456
AUM 626.7 M (2026-03-31)
Employees 5 (80% Investors, 0% Brokers)
Fees
Minimum
Phone929-888-7476
AddressD81 Calle C
Dorado, PR 00646
Source [IAPD] [EDGAR]
Total AUM ($M)
70056042028014002010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5.     Fees and Compensation

The Firm’s fees and compensation are described in its clients’ Governing Documents. All of the Firm’s
clients are “qualified purchasers” (as defined in Section 2(a)(51) of the Investment Company Act of 1940,
as amended).

The Firm is paid management fees from the Flagship Funds quarterly in advance generally at a rate of
2.0% for Class A and 1.5% for Class B. Once paid, such management fees are non-refundable. The Firm
deducts management fees from the Flagship Funds. The Firm may reduce or waive management fees
with respect to any investor (including any affiliates of the Firm). The Firm does not expect that
management fees will be paid with respect to shares or interests of the Flagship Funds held (directly or
indirectly) by or for the benefit of the CIO, the Firm’s employees or their respective affiliates, or immediate
family members of such parties.

The SMA is not subject to management fees.

The Lynx1 GP will be entitled receive performance-based allocations or carried interest from the Funds,
as further described in Item 6 – Performance-Based Fees and Side-By-Side Management.

The Firm’s compensation schedule with respect to any future client account will be contained in the
Governing Documents relating to such account.

The Flagship Funds will bear all of their operating expenses (collectively, the “Flagship Fund Expenses”),
which expenses will include, without limitation: (i) organizational and offering expenses, (ii) expenses
associated with all investments and transactions considered, evaluated and/or consummated by the
Flagship Funds, as well as overall consideration and evaluation of the Flagship Funds’ portfolio, including,
without limitation, those expenses incurred before the initial closing of the Flagship Funds, including,
without limitation, expenses associated with sourcing, negotiating, investigating, researching, financing
and structuring of investments and potential investments, whether or not consummated, including,
without limitation, data and research onboarding, ingestion, aggregation, and analysis, third-party
research, data, analytics, modeling, risk, structuring, pricing, execution and other third-party information
systems, including, without limitation, installation and maintenance, software and service fees (including,
without limitation, the expenses with respect to data, data feeds, subscriptions, expert networks, political
intelligence providers and reports), (iii) the costs of research-related computer hardware and software
expenses, including, without limitation, Bloomberg terminals and subscriptions and other market
information systems, as well as the costs of research management systems and corporate access tracking
systems, (iv) the costs of the Firm’s portfolio management system and any other software used for
accounting and/or monitoring of the portfolio, including, without limitation, subscriptions relating to,
among other things, trading and order management systems and services, (v) expenses associated with
holding, financing, monitoring, hedging, maintaining and disposing of all investments of the Flagship
Funds and all transaction and other costs associated therewith, including, without limitation, expenses
associated with proxy research and voting services, (vi) travel (first-class or equivalent) and related
expenses associated with investments and potential investments, (vii) professional fees associated with
investments and potential investments, including, without limitation, consulting, due diligence,
accounting, valuation, financial, legal and other advisory fees and expenses, (viii) transaction fees,
brokerage commissions, custodial fees, clearing and settlement charges and similar fees and expenses
associated with the acquisition, disposition and settling of investments and potential investments,
including, without limitation, in connection with outsourced trading, (ix) expenses associated with legal
and regulatory filings of the Flagship Funds in the United States, the Cayman Islands or in any other
jurisdiction (including, without limitation, pursuant to Sections 13 and 16 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), as well as the expenses associated with preparation and filing
of the Firm’s Form 13F, Form 13H and Form PF, if applicable, and any other similar filing in any other U.S.
or non-U.S. jurisdiction, (x) administrative, custodial, appraisal, valuation, legal, regulatory, compliance,
consulting, advisory and similar fees and expenses associated with the Flagship Funds’ operations,
investments and transactions, including, without limitation, fees and expenses of the Flagship Funds’
administrator and the costs of client relationship management systems, (xi) expenses incurred in
connection with responding to requests or inquiries from any U.S. federal, state, local or non-U.S.
governmental entity or authority, regulatory body or self-regulatory organization with respect to the
Flagship Funds, (xii) broken-deal, failed transaction, break-up and similar fees, costs and expenses (if any),
(xiii) costs and expenses of leverage or any other borrowings of the Flagship Funds, including, without
limitation, interest charges and fees, (xiv) expenses incurred in the collection of monies owed to the
Funds, (xv) auditing and accounting expenses of the Flagship Funds, including, without limitation,
expenses associated with the preparation of financial statements, tax returns and Schedules K-1 and the
fees and expenses of the auditor, (xvi) any entity-level taxes, fees or other governmental charges on the

Flagship Funds, including, without limitation, any withholding taxes not due to the status or
noncompliance of a particular investor, (xvii) costs and expenses associated with investor communications
and reports and the delivery thereof to investors, (xviii) the costs of service providers or software to
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7.     Types of Clients

Investors in the Funds are generally institutional investors, funds of funds and high net worth individuals
that qualify as “accredited investors” (as defined in Rule 501 under the Securities Act of 1933, as amended)
and qualified purchasers. The minimum initial investment for the Flagship Funds is $5,000,000. The Firm
has waived such minimum and, in its discretion, has the ability to do so in the future under certain
circumstances.

If the Firm determines to require a minimum investment for any future client accounts, it will make that
determination on a case-by-case basis.
CIK Period
0001910456
Sector Form 13F Holdings Value ($M)
Stoke Therapeutics Inc 155.1
GH Research PLC 151.3
Cullinan Oncology Inc 127.4
Agios Pharmaceuticals Inc 88.3
Denali Therapeutics Inc 36.1
C4 Therapeutics Inc 18.4
Frequency Therapeutics Inc 17.4
TScan Therapeutics Inc 8.1
Xencor Inc 6.5
Precision Biosciences Inc 5.4
Bionomics Limited/Fi 3.6
Entrada Therapeutics Inc 2.7
CG Oncology Inc 2.1
Immatics NV 2.1
Design Therapeutics Inc 1.3
Menlo Therapeutics Inc 1.0
Werewolf Therapeutics Inc 0.5
IBIO Inc 0.1
Bolt Biotherapeutics Inc 0.1
Proqr Therapeutics NV 0.1
Absci Corp 0.1
Onconova Therapeutics Inc 0.0
 
 
 
 
 
 
 
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
PE Lynx1 Opportunity Fund I LP 2023-03-03
HF Lynx1 Master Fund LP [2021-10-13] 114.0 M 576.8 M
Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $16,107 · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 5 626.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 5 626.7
By Discretionary
Discretionary 5 626.7
Non-Discretionary 0 0.0
Total 5 626.7
By Non-United States Persons
Non-United States Persons 159.1
United States Persons 467.6
Total 5 626.7
Form D Directors Role # Filings # Firms 2011 - 2026
Matt Auriemma Director 110 39
Wendy Beer Director 19 11
Weston Nichols Director 7 2
Lynx1 Capital Management LP Promoter 2 2
EDGAR Form CIK 2011 - 2026
13F-HR [0001910456]
3 [0001910456]
4 [0001910456]
SC 13D [0001910456]
SC 13G [0001910456]
Form 13D/13G Filer Form 13D/13G Subject Filed
Lynx1 Capital Management LP Precision Biosciences Inc [2026-07-20]
Lynx1 Capital Management LP Passage Bio Inc [2026-07-02]
Lynx1 Capital Management LP Agios Pharmaceuticals Inc [2026-05-06]
Lynx1 Capital Management LP Korro Bio Inc [2026-01-05]
Lynx1 Capital Management LP Neuphoria Therapeutics Inc [2025-10-23]
Lynx1 Capital Management LP Cullinan Therapeutics Inc [2025-08-14]
Lynx1 Capital Management LP Allogene Therapeutics Inc [2025-02-14]
Lynx1 Capital Management LP Precision Biosciences Inc [2025-02-14]
Lynx1 Capital Management LP IBIO Inc [2024-04-01]
Lynx1 Capital Management LP Passage Bio Inc [2024-03-29]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI5493003YH8Q5SHT17216
Form 3/4/5 Subject 2011 - 2026
Nichols Weston
Passage Bio Inc
Lynx1 Capital Management LP
Korro Bio Inc
TScan Therapeutics Inc
Cullinan Therapeutics Inc
Bionomics Limited/Fi
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
TScan Therapeutics Inc TCRX
Common Stock
2025-12-23 Buy 6,232 $0.90 5,609
TScan Therapeutics Inc TCRX
Common Stock
2025-12-22 Buy 75,500 $0.90 67,950
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-12-19 Buy 80,069 $0.90 72,062
Cullinan Therapeutics Inc CGEM
Common stock, $0.0001 par value per share
2025-10-28 Buy 165,667 $8.40 1,391,603
Bionomics Limited/Fi NEUP
Common stock, $0.00001 par value per share
2025-10-21 Buy 639,110 $5.14 3,285,025
Cullinan Therapeutics Inc CGEM
Common Stock
2025-10-17 Buy 32,217 $7.84 252,581
Cullinan Therapeutics Inc CGEM
Common Stock
2025-10-16 Buy 150,000 $8.86 1,329,000
Cullinan Therapeutics Inc CGEM
Common Stock
2025-10-15 Buy 51,500 $7.94 408,910
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-10-14 Buy 15,032 $7.59 114,093
Cullinan Therapeutics Inc CGEM
Common Stock
2025-10-10 Buy 277,298 $7.36 2,040,913
Cullinan Therapeutics Inc CGEM
Common Stock
2025-10-09 Buy 626,043 $6.70 4,194,488
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-10-08 Buy 556,300 $6.46 3,593,698
Passage Bio Inc PASG
Common Stock
2025-07-24 Buy 66,423 $5.71 379,275
Passage Bio Inc PASG
Common Stock
2025-07-23 Buy 49,302 $5.74 282,993
Passage Bio Inc PASG
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-07-22 Buy 13,123 $5.44 71,389
TScan Therapeutics Inc TCRX
Common Stock
2025-05-20 Buy 1,200,000 $1.20 1,440,000
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-05-19 Buy 1,388,794 $1.20 1,666,553
Passage Bio Inc PASG
Common stock, $0.0001 par value per share
2024-12-27 Buy 373,645 $0.65 242,869
TScan Therapeutics Inc TCRX
Pre-funded Warrant (right to buy) · derivative
2024-12-26 Buy 7,500,000 $4.00 30,000,000
TScan Therapeutics Inc TCRX
Common Stock
2024-12-13 Buy 100,000 $2.90 290,000
showing 20 of 29 most recent transactions
Comparable Firms State AUM
M37 Management LP
CA 656.4 M
Altum Capital Management LLC
NY 647.8 M
Standard General LP
NY 647.3 M
Crow's Nest Holdings LP
VA 636.6 M
Rose Park Advisors LLC
MA 629.9 M
Manatuck Hill Partners LLC
CT 628.6 M
Lago Asset Management LLC
IL 604.9 M
Callodine Credit Management LLC
MA 603.0 M
Endeavour Capital Advisors Inc
CT 602.7 M
GFG Alternative Investment Advisors LLC
CT 599.6 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com